GSK Adopting New Marketing Push For Avandia
This article was originally published in The Pink Sheet Daily
Executive Summary
ADOPT trial results, which show rosiglitazone beats metformin for maintaining glycemic control, could double the market for the insulin sensitizer.
You may also be interested in...
GSK “Dear Health Care Provider” Letter Cites Rosiglitazone Fracture Risk In Women
FDA MedWatch alert issued Feb. 20 notes there were “significantly more” fractures in women taking rosiglitazone in the ADOPT trial.
GSK “Dear Health Care Provider” Letter Cites Rosiglitazone Fracture Risk In Women
FDA MedWatch alert issued Feb. 20 notes there were “significantly more” fractures in women taking rosiglitazone in the ADOPT trial.
Avandia Not Losing Market Share To Januvia, GSK Reports
Merck’s DPP-4 inhibitor is largely taking business from metformin and sulfonylureas, GSK exec Stout asserts.